Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 1
2004 3
2005 2
2006 4
2007 1
2008 5
2009 9
2010 5
2011 10
2012 5
2013 7
2014 13
2015 18
2016 15
2017 17
2018 19
2019 21
2020 28
2021 12
2022 18
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.
Dicks EM, Tyrer JP, Ezquina S, Jones M, Baierl J, Peng PC, Diaz M, Goode E, Winham SJ, Dörk T, Van Gorp T, De Fazio A, Bowtell D, Odunsi K, Moysich K, Pavanello M, Campbell I, Brenton JD, Ramus SJ, Gayther SA, Pharoah PDP. Dicks EM, et al. medRxiv [Preprint]. 2024 Apr 3:2024.04.02.24304968. doi: 10.1101/2024.04.02.24304968. medRxiv. 2024. PMID: 38633804 Free PMC article. Preprint.

Seven of the top 10 associated genes were associations of the known ovarian cancer susceptibility genes BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, MSH6 and PALB2 (false discovery probability < 0.1). A further four genes (HELB, OR2T35, NBN and MYO1A) had a false discovery rate

…
Seven of the top 10 associated genes were associations of the known ovarian cancer susceptibility genes BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, …
Mismatch repair gene MSH6 correlates with the prognosis, immune status and immune checkpoint inhibitors response of endometrial cancer.
Zhou LZ, Xiao HQ, Chen J. Zhou LZ, et al. Front Immunol. 2024 Feb 8;15:1302797. doi: 10.3389/fimmu.2024.1302797. eCollection 2024. Front Immunol. 2024. PMID: 38390329 Free PMC article.
To exclude the influence of MSH6 mutations, we performed the previous analyses on the MSH6 wild-type tumor samples and obtained consistent results. ...MSH6 may become a potential target for treating solid tumors....
To exclude the influence of MSH6 mutations, we performed the previous analyses on the MSH6 wild-type tumor samples and obtaine …
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
Khushman MM, Toboni MD, Xiu J, Manne U, Farrell A, Lou E, Shields AF, Philip PA, Salem ME, Abraham J, Spetzler D, Marshall J, Jayachandran P, Hall MJ, Lenz HJ, Sahin IH, Seeber A, Powell MA. Khushman MM, et al. Clin Cancer Res. 2024 May 1;30(9):1906-1915. doi: 10.1158/1078-0432.CCR-23-3004. Clin Cancer Res. 2024. PMID: 38350001
RESULTS: Compared with mutL (MLH1 and PMS2) co-loss, the mOS was longer in mutS (MSH2 and MSH6) co-loss in all colorectal cancer (54.6 vs. 36 months; P = 0.0.025) and endometrial cancer (81.5 vs. 48.2 months; P < 0.001) patients. ...
RESULTS: Compared with mutL (MLH1 and PMS2) co-loss, the mOS was longer in mutS (MSH2 and MSH6) co-loss in all colorectal cancer (54. …
Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment.
Higuchi F, Uzuka T, Matsuda H, Sumi T, Iwata K, Namatame T, Shin M, Akutsu H, Ueki K. Higuchi F, et al. Brain Tumor Pathol. 2024 Apr;41(2):80-84. doi: 10.1007/s10014-024-00477-w. Epub 2024 Jan 31. Brain Tumor Pathol. 2024. PMID: 38294664
The recurrent tumor responded well to TMZ but developed a rapid progression after 6 cycles as a malignant hypermutator tumor with a MSH6 mutation. Most of the recurrent tumor lacked typical oligodendroglioma morphology that was observed in the primary tumor, while it retai …
The recurrent tumor responded well to TMZ but developed a rapid progression after 6 cycles as a malignant hypermutator tumor with a MSH6 …
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD).
Incorvaia L, Badalamenti G, Novo G, Gori S, Cortesi L, Brando C, Cinieri S, Curigliano G, Ricciardi GR, Toss A, Chiari R, Berardi R, Ballatore Z, Bono M, Bazan Russo TD, Gristina V, Galvano A, Damerino G, Blasi L, Bazan V, Russo A. Incorvaia L, et al. ESMO Open. 2024 Jan;9(1):102196. doi: 10.1016/j.esmoop.2023.102196. Epub 2023 Dec 19. ESMO Open. 2024. PMID: 38118367 Free PMC article.
The left ventricular ejection fraction (LVEF) was assessed using cardiac ultrasound before starting ACR therapy and at subsequent time points according to clinical indications. RESULTS: Five hundred and three BC patients were included in the study. ...To assess the relevan …
The left ventricular ejection fraction (LVEF) was assessed using cardiac ultrasound before starting ACR therapy and at subsequent time point …
Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study).
Hawranek C, Ehrencrona H, Öfverholm A, Hellquist BN, Rosén A. Hawranek C, et al. Trials. 2023 Dec 17;24(1):810. doi: 10.1186/s13063-023-07829-5. Trials. 2023. PMID: 38105176 Free PMC article.
In this study, we evaluate healthcare-assisted direct letters to relatives at risk of hereditary cancer syndromes in a randomized controlled trial. METHODS: Probands are recruited from Swedish outpatient cancer genetics clinics to this two-arm randomized cont …
In this study, we evaluate healthcare-assisted direct letters to relatives at risk of hereditary cancer syndromes in a randomized con …
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, Ariyama H, Kanai M, Kamikura M, Anjo K, Hiramitsu A, Sekine S, Okita N, Mano H, Nishikawa H, Nakamura K, Yonemori K. Okuma HS, et al. Clin Cancer Res. 2023 Dec 15;29(24):5079-5086. doi: 10.1158/1078-0432.CCR-23-1807. Clin Cancer Res. 2023. PMID: 37819940 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: We conducted a multicenter phase II, open-label, single-arm clinical trial to explore the effectiveness and safety of nivolumab monotherapy in patients with advanced rare cancers with dMMR/MSI-H, in parallel with immune phenotype analysis, to e …
PATIENTS AND METHODS: We conducted a multicenter phase II, open-label, single-arm clinical trial to explore the effectiveness …
Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells.
Paul S, Chatterjee S, Sinha S, Dash SR, Pradhan R, Das B, Goutam K, Kundu CN. Paul S, et al. Expert Opin Ther Targets. 2023 Jul-Dec;27(10):999-1015. doi: 10.1080/14728222.2023.2266572. Epub 2023 Oct 30. Expert Opin Ther Targets. 2023. PMID: 37787493
After 5-FU treatment, PARylated-PARP1 activated MMR pathway by interacting with MSH6. But, upon ABT-888 treatment in 5-FU-pre-exposed CSCs, PARylation was inhibited, as a result of which PARP1 could not interact with MSH6, and other MMR proteins were downregulated. …
After 5-FU treatment, PARylated-PARP1 activated MMR pathway by interacting with MSH6. But, upon ABT-888 treatment in 5-FU-pre-exposed …
Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer.
Wang CW, Lee YC, Lin YJ, Firdi NP, Muzakky H, Liu TC, Lai PJ, Wang CH, Wang YC, Yu MH, Wu CH, Chao TK. Wang CW, et al. Lab Invest. 2023 Nov;103(11):100247. doi: 10.1016/j.labinv.2023.100247. Epub 2023 Sep 22. Lab Invest. 2023. PMID: 37741509
Vascular endothelial growth factors have been identified as inducing tumor angiogenesis. According to several clinical trials, anti-vascular endothelial growth factor-targeted therapy with bevacizumab was effective in all phases of EOC treatment. ...In prediction of therap …
Vascular endothelial growth factors have been identified as inducing tumor angiogenesis. According to several clinical trials, anti-v …
212 results